Vinorelbine Ditartrate

Breast Disorder

Sun Yat-sen UniversitySmall moleculePhase 2Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

24 Active assets in the Breast Disorder cohort.

Asset / Sponsor	Phase	Rating
Trastuzumab Incepta Pharmaceuticals Ltd	Phase 3	BB
Sacubitril Valsartan Silesian Centre for Heart Diseases	Phase 4	BB
Olaparib AstraZeneca	Phase 2	BB
Capecitabine University of Southern California	Phase 3	B
Letrozole Fujian Cancer Hospital	Phase 2/3	B

View all 45 →

Same molecule, other indications

Vinorelbine Ditartrate is also rated in:

Hodgkins lymphomaActive

BBB

Indicative · Phase 3

72 / 100

cervical cancerDormant

BBB

Indicative · Phase 2

72 / 100

non-small cell lung carcinomaActive

BB

Indicative · Phase 4

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.